Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying

J Arts, P Caenepeel, K Verbeke, J Tack


**Background and aims:** Although delayed gastric emptying is considered a major pathophysiological mechanism underlying symptoms in functional dyspepsia and idiopathic gastroparesis, several studies have investigated the relationship between delayed gastric emptying and symptom pattern and severity. Depending on the study, the percentage of dyspeptic patients with delayed gastric emptying ranges from 25% to 50%. Most studies failed to find a relationship between delayed gastric emptying and symptom pattern. Delayed gastric emptying for solids were more likely to report postprandial fullness, nausea, and vomiting. The relationship between symptom pattern and the presence of delayed emptying suggests a possible pathophysiological role for delayed gastric emptying in eliciting dyspeptic symptoms such as fullness, nausea, and vomiting. Patients with delayed gastric emptying are usually treated with gastroprokinetic drugs such as metoclopramide, domperidone, and previously also cisapride, although a relationship between improvement in gastric emptying rate and symptomatic benefit has not been proved. However, the gastroprokinetic effects of these drugs are limited, and the finding of strong gastrokinetic actions for erythromycin, a macrolide antibiotic that acts as a motilin receptor agonist, was met with great enthusiasm. Several short-term studies showed that patients with delayed gastric emptying for solids were more likely to report postprandial fullness, nausea, and vomiting. It has been argued that the negative outcomes of the studies with ABT-229 demonstrate that acceleration of gastric emptying is not the correct therapeutic target in functional dyspepsia. However, there is a strong risk of tachyphylaxis with macrolide prokinetics, and especially with ABT-229. Hence, as measurement of gastric emptying was not repeated at the time of symptom assessment in the ABT-229 studies, the relationship between changes in gastric emptying rate and changes in symptom severity in gastroparesis has remained unclear.

The aim of the present study was to investigate the effect of a strong prokinetic on symptom severity in patients with gastroparesis. To overcome problems related to tachyphylaxis, the drug or placebo was administered acutely before a standardised meal and we quantified meal induced dyspeptic symptoms.

**MATERIALS AND METHODS**

**Study subjects**
Consecutive patients with functional dyspepsia were recruited for a validation study. Consecutive functional dyspepsia patients with previously established delayed gastric emptying were recruited for a pharmacological intervention study. Patients presented to the motility outpatient clinic because of symptoms suggestive of gastroparesis, and all underwent careful history taking and clinical examination, routine biochemistry, upper gastrointestinal endoscopy, upper abdominal ultrasound, and a gastric emptying breath test. In all patients with severely delayed emptying, a small bowel x-ray was also performed to rule out small bowel lesions or stenosis. Exclusion criteria were the presence of oesophagitis, gastric atrophy or erosive gastroduodenal lesions on endoscopy, the presence of lesions on small bowel

**Methods:** In 20 patients with functional dyspepsia, gastric emptying was studied twice using the $^{14}$C octanoic acid and $^{13}$C glycin breath test to establish the reproducibility of the test. Breath samples were taken before the meal and at 15 minute intervals for a period of 240 minutes postprandially. At each breath sampling, the patient was asked to grade the intensity (0–3) of six dyspeptic symptoms. Twenty-four patients (three men, mean age 43.5 (3) years) with dyspeptic symptoms and delayed gastric emptying were studied twice after pretreatment with saline or erythromycin intravenously.

**Results:** Meal related symptom severity scores were reproducible. Treatment with erythromycin significantly enhanced solid and liquid gastric emptying ($t_{1/2}$ 146 (27) vs 72 (7) minutes, respectively ($p<0.01$), and 87 (6) vs 63 (5) minutes ($p<0.001$)). Only the severity of bloating was significantly improved by erythromycin ($23 (3.9)$ vs $14.5 (2.7); p<0.01$); all other symptoms and the cumulative meal related symptom score were not altered by erythromycin.

**Conclusions:** In a setting where desensitisation played no role, erythromycin enhanced gastric emptying was not associated with a beneficial effect on meal related symptom severity.
x ray, major abdominal surgery, underlying psychiatric illness, and the use of non-steroidal anti-inflammatory drugs, steroids, or drugs affecting gastric acid secretion.

Each patient completed a symptom questionnaire as reported previously. The patient was asked to grade the intensity (0–3; 0 = absent, 1 = mild, 2 = relevant, and 3 = severe) of eight different symptoms (epigastric pain, bloating, postprandial fullness, early satiety, nausea, vomiting, belching, and epigastric burning) over the last three months. Also, the amount of weight lost since the onset of symptoms was noted.

All drugs potentially affecting gastrointestinal motility or sensitivity were discontinued at least one week prior to the gastric emptying studies. Informed consent was obtained from each participant. The protocol was previously approved by the ethics committee of the University Hospital.

Gastric emptying breath test with assessment of meal related symptoms

Gastric emptying rates for solids and liquids were determined using the 13C octanoic acid and 13C glycin breath test. This test has previously been extensively validated. The test meal consisted of 60 g of white bread, an egg, the yolk of which was doped with 74 kBq of 13C octanoic acid sodium salt (DuPont, NEN Research, Boston, Massachusetts, USA), and 300 ml of water in which 100 mg 13C glycin (99% enrichment; Isotec, Miamisburg, Ohio, USA) was dissolved. All meals were consumed within a five minute period. The total caloric value of the test meal was 250 kcal. Breath samples were taken before the meal and at 15 minute intervals for a period of 240 minutes postprandially. At each sampling point, the subject exhaled into two different containers for measuring exhaled 13C and 14C, respectively. One was a liquid scintillation vial containing 2 ml of M hyamine hydroxide and 2 ml of ethanol together with 1 drop of thymolphthalein solution. This amount of hyamine is neutralised by 2 mM CO2. The end point of neutralisation is indicated by decolouration of the indicator. After decolouration, 10 ml of scintillation cocktail (Hionic Fluor; Packard Instrument Co., Downers Grove, Illinois, USA) was added and radiation was determined by liquid scintillation spectrometry (Packard Tri-Carb Liquid Scintillation Spectrometer, model 3375; Packard Instrument Co.). For 13C measurements, breath was collected by blowing directly into a tube.

At each breath sampling, the patient was asked to grade the intensity (0–3; 0 = absent, 1 = mild; present in a non-bothersome intensity, 2 = relevant: clearly present and bothersome but not of such intensity that it would interfere with normal daily activities, and 3 = severe: clearly present and of such intensity that it would interfere with normal daily activities) of six different symptoms (epigastric pain, bloating, postprandial fullness, nausea, belching, and epigastric burning). We have previously shown that this questionnaire, when used over a time period of one week, shows excellent reproducibility. In the present study, we used this questionnaire, limited to regular postprandially occurring symptoms, and assessing only the period since the onset of symptoms was noted.

Reproducibility of gastric emptying and meal related symptoms

To assess the reproducibility of the gastric emptying test with meal related symptoms, 20 patients underwent two gastric emptying breath tests with assessment of meal related symptoms, approximately two months apart. All drugs potentially affecting gastrointestinal motility or sensitivity were discontinued at least one week prior to the gastric emptying studies.

Studies on the influence of erythromycin on gastric emptying and meal related symptoms

To assess the influence of erythromycin, 24 patients underwent two gastric emptying breath tests with assessment of meal related symptoms, approximately one month apart. All drugs potentially affecting gastrointestinal motility or sensitivity were discontinued at least one week prior to the gastric emptying studies. At the start of the meal, saline or erythromycin 200 mg were infused intravenously over 20 minutes in a double blind, randomised, crossover design.

The order of saline and erythromycin treatment was randomised by drawing cards from a box of cards determining the sequence. A study nurse who was otherwise not involved in the study administered the medication. Half of the subjects received saline first; the other half received erythromycin first.

Data analysis

Symptom scores were obtained before and for four hours after the standardised meal. For each symptom, a meal related severity score was obtained by adding scores at all time points. A cumulative meal related symptom score was obtained by adding individual symptom severity scores.

The 13C breath content was determined by online gas chromatographic purification-isotope ratio mass spectrometry (ABCA; Europe Scientific, Crewe, UK). For both carbon labels, CO2 production was assumed to be 300 mmol/m2 of body surface per hour. Body surface area was calculated by the height-weight formula of Haycock and colleagues. The results of the 13CO2 and 14CO2 breath tests were expressed as percentage 13CO2 and 14CO2, respectively, excreted per hour by calculating procedures described elsewhere. Half gastric half emptying time (t1/2) was calculated from 13CO2 and 14CO2 content of breath samples, as previously described.

Statistical analysis

Results are expressed as mean (SEM). The Student’s t test was used to compare results on different days or after different pretreatments. A p value <0.05 was considered significant. The reproducibility of measurements was evaluated comparing results between the two sessions by paired two tailed t test and by linear correlation analysis where indicated. Bonferroni’s correction for multiple comparisons was applied.

The variability of the test was quantified by calculating the individual coefficient of variation expressed as a percentage (CV = SD of the difference between both measurements, divided by the mean value, and expressed as a percentage). Based on the variability of the test results, the erythromycin study was estimated to have more than 80% power to detect 35% changes in symptom scores at a 0.05 significance level.

RESULTS

Patient characteristics

Forty four patients (37 women, seven men; aged 17–70 years (mean 43.1 (2.1)) with longstanding dyspeptic symptoms were recruited into the study. Previous studies had established a mean half emptying time for solids of 123 (16) minutes and for liquids 78 (4) minutes. Table 1 summarises the grading of dyspeptic symptoms in the patient group. Postprandial fullness and bloating were the most prevalent symptoms, present in 86% and 84% of patients, respectively. Epigastric pain (77%), early satiety (66%), nausea (70%), and belching (68%) were also frequently reported. Vomiting and epigastric burning sensations were present in 39% and 64% of patients, respectively. Weight loss in excess of 5% was present in 22 patients (50%). Seven patients (16%) had Helicobacter pylori infection on gastric biopsies.
Reproducibility of gastric emptying and meal related symptoms

Twenty patients (16 women and four men; mean age 42.6 (2.6) years, body mass index 21.1 (1.2) kg/m²) with longstanding dyspeptic symptoms were recruited for this part of the study. During the first gastric emptying breath test, half emptying times for solids and liquids were 94.7 (12.6) and 67.3 (5.2) minutes, respectively. During the first test, five patients had delayed emptying for solids (t₁/₂ >109 minutes) compared with previously established normal values. The second emptying test confirmed delayed emptying in only three of these, and three other patients with previously normal emptying were also delayed. Meal related symptom severity scores are summarised in table 2. The highest symptom severity scores were obtained for bloating and fullness, while epigastric burning was less prominent. No significant correlation was found between cumulative or individual meal related symptom scores and solid or liquid emptying times.

The gastric emptying test with meal related symptoms was repeated 63 (7) days later. The results and reproducibility are summarised in fig 1 and table 2. Emptying times, meal related symptom severity scores, and cumulative symptom severity scores did not differ significantly and were significantly correlated (all r values >0.58; all p values <0.01). The best reproducibility and lowest variability were found for the cumulative symptom score and meal related scores for fullness, bloating, and pain. As illustrated in fig 1B, the evolution of symptom severity during the four hour postprandial time window also showed excellent reproducibility. Solid and liquid emptying times showed the greatest variability (table 2).

Influence of erythromycin on gastric emptying and meal related symptoms

Twenty four patients (21 women and three men; mean age 43.5 (3.2) years, body mass index 22.2 (0.8) kg/m²) with longstanding dyspeptic symptoms and previously established delayed gastric emptying were recruited for this part of the study. They underwent two gastric emptying tests with administration of saline or erythromycin on average 26 (8) days apart. After administration of saline, both solid and liquid gastric emptying were clearly delayed (t₁/₂ 146 (27) and 87 (6) minutes, respectively), as expected on the basis of selection of patients. The cumulative and individual meal related symptom severity scores are summarised in fig 2.

After administration of erythromycin, both solid and liquid gastric emptying times were significantly enhanced (t₁/₂ 72 (7) and 63 (5) minutes, respectively; both p<0.01 compared with saline). However, the cumulative meal related symptom score was not altered by pretreatment with erythromycin (fig 2A). Similarly, except for bloating, none of the individual symptom severity scores improved after administration of erythromycin (figs 2, 3).

No significant correlation was found between changes in cumulative or individual meal related symptom scores and changes in solid half emptying times.

### Table 1
Frequency of severity grading for each of eight dyspepsia symptoms in 44 patients with functional dyspepsia

<table>
<thead>
<tr>
<th>Symptom</th>
<th>0 (absent)</th>
<th>1 (mild)</th>
<th>2 (relevant)</th>
<th>3 (severe)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Postprandial fullness</td>
<td>6 (14)</td>
<td>3 (7)</td>
<td>17 (39)</td>
<td>18 (41)</td>
</tr>
<tr>
<td>Bloating</td>
<td>7 (16)</td>
<td>5 (11)</td>
<td>19 (43)</td>
<td>13 (30)</td>
</tr>
<tr>
<td>Epigastric pain</td>
<td>10 (23)</td>
<td>7 (16)</td>
<td>13 (30)</td>
<td>14 (32)</td>
</tr>
<tr>
<td>Early satiety</td>
<td>15 (34)</td>
<td>6 (14)</td>
<td>8 (18)</td>
<td>15 (34)</td>
</tr>
<tr>
<td>Nausea</td>
<td>13 (30)</td>
<td>11 (25)</td>
<td>8 (18)</td>
<td>12 (27)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>27 (61)</td>
<td>6 (14)</td>
<td>4 (9)</td>
<td>7 (16)</td>
</tr>
<tr>
<td>Belching</td>
<td>14 (32)</td>
<td>11 (25)</td>
<td>14 (32)</td>
<td>5 (11)</td>
</tr>
<tr>
<td>Epigastric burning</td>
<td>16 (36)</td>
<td>9 (20)</td>
<td>13 (30)</td>
<td>6 (14)</td>
</tr>
</tbody>
</table>

Values are numbers (row percentages).

### Table 2
Reproducibility of gastric emptying and meal related symptom scores in 20 patients with functional dyspepsia

<table>
<thead>
<tr>
<th>Measurement</th>
<th>1st emptying test</th>
<th>2nd emptying test</th>
<th>CV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solid t₁/₂ (min)</td>
<td>86 (7)</td>
<td>90 (7)</td>
<td>73</td>
</tr>
<tr>
<td>Liquid t₁/₂ (min)</td>
<td>67 (5)</td>
<td>69 (5)</td>
<td>67</td>
</tr>
<tr>
<td>Cumulative symptom score</td>
<td>113 (16)</td>
<td>116 (19)</td>
<td>48</td>
</tr>
<tr>
<td>Fullness</td>
<td>28 (5)</td>
<td>27 (5)</td>
<td>59</td>
</tr>
<tr>
<td>Bloating</td>
<td>25 (5)</td>
<td>25 (5)</td>
<td>30</td>
</tr>
<tr>
<td>Belching</td>
<td>21 (3)</td>
<td>20 (4)</td>
<td>49</td>
</tr>
<tr>
<td>Nausea</td>
<td>17 (4)</td>
<td>18 (4)</td>
<td>41</td>
</tr>
<tr>
<td>Epigastric pain</td>
<td>15 (4)</td>
<td>18 (5)</td>
<td>14</td>
</tr>
<tr>
<td>Epigastric burning</td>
<td>7 (3)</td>
<td>8 (4)</td>
<td>40</td>
</tr>
</tbody>
</table>

Half emptying times (t₁/₂) and symptom severity scores for repeated testing are shown, as well as the coefficient of variability (CV %) between the results of both tests.
significant heterogeneity between studies was present. It has been reported that prokinetics were more related to enhancement of gastric emptying is lacking. Traditionally, prokinetic agents, including metoclopramide, erythromycin, and several motilin agonists lacking antibiotic activity were developed. One of them, ABT-229, was evaluated in large controlled studies but no favourable effect was observed in patients or in those with established delayed gastric emptying. Based on the negative outcome of the ABT-229 studies, it was suggested that enhancing gastric emptying was not a useful target in the treatment of dyspeptic symptoms. However, the reasons for the negative results are unclear, and apart from interference of the drug with gastric accommodation, desensitisation of the motilin receptor was also suggested as a possible explanation.

In the present study, we evaluated the symptomatic effect of a motilin receptor agonist during acute administration, thereby avoiding interference from receptor desensitisation. Firstly, we established that gastric emptying with meal related symptom assessment was reproducible in functional dyspepsia. It has been reported that scintigraphic gastric emptying rate and any of the dyspeptic symptoms. However, the latter study involved 395 subjects, and the results are unclear, and apart from interference of the drug with gastric accommodation, desensitisation of the motilin receptor was also suggested as a possible explanation.

Erythromycin, a macrolide antibiotic, was the first compound of a new class of gastroprokinetics that act through agonism at the motilin receptor on nerves and smooth muscle in the stomach. Compared with previously existing prokinetics, erythromycin has stronger effects on gastric motility, and several motilin agonists lacking antibiotic activity were developed. One of them, ABT-229, was evaluated in large controlled studies but no favourable effect was observed in patients or in those with established delayed gastric emptying. Based on the negative outcome of the ABT-229 studies, it was suggested that enhancing gastric emptying was not a useful target in the treatment of dyspeptic symptoms. However, the reasons for the negative results are unclear, and apart from interference of the drug with gastric accommodation, desensitisation of the motilin receptor was also suggested as a possible explanation.

In the present study, we evaluated the symptomatic effect of a motilin receptor agonist during acute administration, thereby avoiding interference from receptor desensitisation. Firstly, we established that gastric emptying with meal related symptom assessment was reproducible in functional dyspepsia. It has been reported that scintigraphic gastric emptying rate and any of the dyspeptic symptoms. However, the latter study involved 395 subjects, and the results are unclear, and apart from interference of the drug with gastric accommodation, desensitisation of the motilin receptor was also suggested as a possible explanation.

Erythromycin, a macrolide antibiotic, was the first compound of a new class of gastroprokinetics that act through agonism at the motilin receptor on nerves and smooth muscle in the stomach. Compared with previously existing prokinetics, erythromycin has stronger effects on gastric motility, and several motilin agonists lacking antibiotic activity were developed. One of them, ABT-229, was evaluated in large controlled studies but no favourable effect was observed in patients or in those with established delayed gastric emptying. Based on the negative outcome of the ABT-229 studies, it was suggested that enhancing gastric emptying was not a useful target in the treatment of dyspeptic symptoms. However, the reasons for the negative results are unclear, and apart from interference of the drug with gastric accommodation, desensitisation of the motilin receptor was also suggested as a possible explanation.
with previous studies,15 17–19 we confirmed that acute administration of erythromycin significantly enhanced gastric emptying of both solids and liquids. We confirmed some therapeutic potential of prokinetic treatment, as we observed significant improvement in bloating after administration of erythromycin compared with placebo. The improvement in bloating scores was not significantly correlated with changes in gastric half emptying time, but other aspects of prokinetic activity such as intragastric distribution, lag time, and emptying rates over time after the meal were not assessed. Furthermore, it remains to be established whether this decrease in bloating severity of approximately 35% is clinically meaningful. However, the study also confirmed the limitations of the therapeutic potential of this class of prokinetics, as other symptoms, as well as cumulative meal related symptoms, were not improved by erythromycin.

The symptoms of postprandial fullness and nausea, associated with delayed gastric emptying in a number of studies,10–12 were not influenced by erythromycin treatment, which significantly enhanced the gastric emptying rate. These observations suggest that there is no direct relationship between delayed gastric emptying and the severity of these symptoms. It is conceivable that a hitherto unclarified mechanism induces both delayed emptying and symptoms of fullness, nausea, and vomiting. On the other hand, it is conceivable that improvement of certain symptoms, unrelated to enhanced gastric emptying, would require prolonged exposure to prokinetics, and the inability to detect such influences is a clear limitation of the present study design. The findings of this study cannot be extrapolated to prokinetics that do not act through the motilin receptor. It is well established that erythromycin and related compounds impair gastric accommodation to a meal,20 21 thereby enhancing sensitivity to gastric distension,22 which may have contributed to the overall poor symptomatic effect. The prokinetic 5-hydroxytryptamine-4 receptor agonists cisapride and tegaserod were shown to enhance gastric accommodation to a meal23 24 and are therefore less likely to worsen or induce symptoms related to impaired accommodation. If the lack of overall symptomatic effect of erythromycin is related to its effect on the proximal stomach, more selective motilin receptor agonists that are devoid of an effect on the proximal stomach might be useful. Both in vitro and in vivo studies have shown that erythromycin can activate motilin receptors on gastric smooth muscle and on intrinsic cholinergic nerves.25 26 In human and rabbit antrum, the effects of lower doses of erythromycin are neurally mediated whereas higher doses induce direct muscular effects.27 28 As the effects of motilin receptor activation on the proximal stomach are direct smooth muscle effects,29 motilin receptor agonists with selectivity for the putative neural receptors might have a better symptomatic effect.

In summary, we have shown that acute administration of erythromycin in patients with functional dyspepsia and delayed gastric emptying enhances gastric emptying and improves meal induced bloating. Other dyspeptic symptoms, including postprandial fullness and nausea, were not significantly altered by erythromycin, and the cumulative meal related symptom severity score was not improved. These findings suggest that the therapeutic effect of currently available motilin receptor agonists in the treatment of functional dyspepsia is at best modest.

References

EDITOR’S QUIZ: GI SNAPSHOT

An unusual cause of abdominal pain in a patient with hepatitis C cirrhosis

A 51 year man with a history of hepatitis C cirrhosis presented with a two day history of fever, malaise, abdominal distension, and severe abdominal pain in his right upper quadrant. On examination he had significant tenderness and guarding in his right upper quadrant. A computed tomography scan revealed a nodular and cirrhotic liver, moderate ascites, and enlarged spleen (fig 1A). There was air within the superior mesenteric veins (arrows) along with marked bowel wall thickening at the hepatic flexure and pneumatisis (arrowheads) suggesting necrotic bowel (fig 1A). He was taken to the operating room for an exploratory laparotomy that revealed a severely inflamed, enlarged, and indurated right hemicolon, without perforation. Right hemicolecotomy with an end to end ileocolic anastomosis was successfully performed. The histology of the resected specimen is displayed in fig 1B.

Question
What is the diagnosis?
See page 521 for answer

This case is submitted by:

A Cárdenas, N H Afdhal
Liver Center, Department of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA

Correspondence to: Dr A Cárdenas, Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis St Ste 8E, Boston, MA 02215, USA; acardena@bidmc.harvard.edu
doi: 10.1136/gut.2004.049122
An unusual cause of abdominal pain in a patient with hepatitis C cirrhosis

A Cárdenas, N H Afdhal and K Khwaja

Gut 2005 54: 460
doi: 10.1136/gut.2004.049122

Updated information and services can be found at:
http://gut.bmj.com/content/54/4/460

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/